DRUG PRICING
TODAY'S HEADLINES
Express Scripts will implement more programs that pay for drugs based on their effectiveness in studies, after success with its Oncology Care Value Program. Read more |
|
FDA recently fast-tracked approval of cabozantinib (Cabometyx, Exelixis, Inc.) to treat advanced renal cell carcinoma. Here are the top 5 facts about Cabometyx. Read more
|
CONTINUING PHARMACY EDUCATION
This month's CE activity, "Keep your patient moving: An overview of treatment options for constipation," is open for pharmacists and pharmacy technicians.
The goal of this program is to assist pharmacists and pharmacy technicians in their understanding of the role of linaclotide, lubiprostone, methylnaltrexone, and naloxegol in the treatment of constipation after conventional nonpharmacologic interventions and conventional laxatives such as bulking agents, osmotic laxatives, and stimulant laxatives have failed.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
The pricing of oncology drugs is not necessarily based on their novelty or effectiveness, according to a JAMA Oncology study. Instead, researchers found, "current pricing models are not rational but simply reflect what the market will bear."
Read more
|
|
|
